Deals Shaping The Medical Industry, December 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.
You may also be interested in...
Developers of medicines that benefit from the European Medicines Agency’s priority medicines scheme can expect to be eligible for accelerated assessment when they eventually file for approval. But there have been no new entries to the scheme for two months now.
Four $2bn+ alliances were penned in July. Topping the list was a potential $2.4bn deal between Arvinas and Pfizer under which the Big Pharma received worldwide co-exclusive rights to develop and commercialize products containing Arvinas’ ARV-471. ARV-471 is in a Phase II dose expansion clinical trial for the treatment of patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Preclinical and early clinical data for ARV-471 as a single agent and in combination with Ibrance was a key contributor in Pfizer’s decision to partner with Arvinas.
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.